# BMT CTN Core- University of Pennsylvania Abramson Cancer Center

> **NIH NIH UG1** · UNIVERSITY OF PENNSYLVANIA · 2024 · $243,750

## Abstract

PROJECT SUMMARY/ABSTRACT
The PENN Medicine Cell Therapy and Transplant Program (PENN CTT) is among the largest and oldest
hematopoietic cell transplant (HCT) programs in the nation. This active program sees patients of all genders,
races, ethnicities, socioeconomic status and individuals with disabilities and disadvantaged backgrounds. PENN
CTT conducts all forms of HCT including autologous and allogeneic (myeloablative and reduced intensity) from
all sources including cord blood, matched and mismatched related and unrelated donors and has been a pioneer
in gene modified T cell therapies for a myriad of malignant and non-malignant diseases. Dr. Edward Stadtmauer
has been the PI of this BMT CTN CCC since its founding in 2001, currently the Chair of the Steering Committee,
and has a number of leadership positions at PENN Medicine including Hematology-Oncology Division,
Abramson Cancer Center (ACC) and the Cancer Service Line so access to institutional resources and patients
for BMT CTN clinical trials is straightforward and this has been reflected in the strong accrual from our center.
Dr. David Porter, the Director of the CTT Program and President-elect of the ASTCT is a co-investigator of this
CCC for over 20 years. Additionally, two new co-investigators, Drs Elizabeth Hexner, Medical Director for our
Center for Cellular Immunotherapies (CCI), and Noelle Frey, Director of Cellular Therapy have been very active
in the Network activities and are well positioned for leadership succession. 587 patients have been accrued from
PENN CTT to BMT CTN; among the top 10 of >140 centers participating. PENN CTT has demonstrated
substantial intellectual leadership in the Network. PENN CTT investigators have served as members on 18
protocol teams (study chairs for 6) and members of 8 administrative and technical committees (chair of 3). PENN
CTT remains consistently very active with 2175 HCTs conducted in 2018-2022; 1446 autologous, 628 allogeneic
and 599 cellular therapies. The PENN CTT is supported by numerous world-class HCT patient care and research
resources including the ACC which was ranked ‘Exceptional’ as a NCI CCC in 2020; the CCI led by our pioneer
cellular immunobiologist Dr. Carl June; and the PENN-CHOP Blood Center focused on non-malignant blood
disorders run by Charles Abrams a renowned hematologist and past President ASH. Our research proposal, “A
phase 2 trial for patients with B cell Acute Lymphoblastic Leukemia (ALL) who achieve a measurable
residual disease (MRD) negative remission after brexu-cel randomized to a second infusion of brexu-cel
versus allogeneic HSCT or observation” was chosen among many alternatives from Penn to demonstrate an
area of our expertise, based on our own pilot study work, fill a major clinical need and can be completed in a
timely fashion. These attributes of strong clinical research, patient care, thought leaders in the field and
a documented enthusiasm for and success in BMT CTN trials uniquely position PENN CTT t...

## Key facts

- **NIH application ID:** 10939829
- **Project number:** 2UG1HL069286-24
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Edward A Stadtmauer
- **Activity code:** UG1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $243,750
- **Award type:** 2
- **Project period:** 2001-09-30 → 2031-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10939829

## Citation

> US National Institutes of Health, RePORTER application 10939829, BMT CTN Core- University of Pennsylvania Abramson Cancer Center (2UG1HL069286-24). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/10939829. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*